Optimization of metabolism to improve efficacy during CAR-T cell manufacturing

J Transl Med. 2021 Dec 7;19(1):499. doi: 10.1186/s12967-021-03165-x.

Abstract

Chimeric antigen receptor T cell (CAR-T cell) therapy is a relatively new, effective, and rapidly evolving therapeutic for adoptive immunotherapies. Although it has achieved remarkable effect in hematological malignancies, there are some problems that remain to be resolved. For example, there are high recurrence rates and poor efficacy in solid tumors. In this review, we first briefly describe the metabolic re-editing of T cells and the changes in metabolism during the preparation of CAR-T cells. Furthermore, we summarize the latest developments and newest strategies to improve the metabolic adaptability and antitumor activity of CAR-T cells in vitro and in vivo.

Keywords: CAR-T; Glycolysis; Immunotherapy; Metabolism; OXPHOS.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Hematologic Neoplasms* / pathology
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms*
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Chimeric Antigen* / metabolism
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen